FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver

Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model

(2018) François Briand et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice

(2017) Jan Freark de Boer et al.   GASTROENTEROLOGY

Serum cholesterol changes associated with NGM282 treatment in obese insulin resistant cynomolgus monkeys are reversed with either a statin or a PCSK9 inhibitor

(2017) J. Luo et al.   JOURNAL OF HEPATOLOGY

Targeting the gut-liver axis in liver disease

(2017) Reiner Wiest et al.   JOURNAL OF HEPATOLOGY

Steroidal or non-steroidal FXR agonists – Is that the question?

(2017) Len Verbeke et al.   JOURNAL OF HEPATOLOGY

Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III

(2017) M. Ghosh Laskar et al.   JOURNAL OF INTERNAL MEDICINE

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

(2017) David C. Tully et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers

(2016) R. Pencek et al.   DIABETES OBESITY & METABOLISM

Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice

(2016) Yang Xu et al.   HEPATOLOGY

Fxr Agonism by Gs-9674 Decreases Steatosis and Fibrosis in a Murine Model of Nash

(2016) J.T. Liles et al.   JOURNAL OF HEPATOLOGY

Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters

(2016) Bin Dong et al.   JOURNAL OF LIPID RESEARCH

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

(2016) Frederik Nevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease

(2016) Claudia Fuchs et al.   SEMINARS IN LIVER DISEASE

Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers

(2015) Willscott E. Naugler et al.   GASTROENTEROLOGY

LP18 : Obeticholic acid for NASH: benefits in a high risk subgroup and the effects of concomitant statin use

(2015) B. Neuschwander-Tetri et al.   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice

(2015) Chise Tateno et al.   PLoS One

Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice

(2014) Zidong Donna Fu et al.   JOURNAL OF LIPID RESEARCH

Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: An experimental study in the rabbit

(2014) Linda Vignozzi et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Pleiotropic Roles of Bile Acids in Metabolism

(2013) Thomas Q. de Aguiar Vallim et al.   Cell Metabolism

Mice With Human Livers

(2013) Markus Grompe et al.   GASTROENTEROLOGY

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS

(2013) Elena Maneschi et al.   JOURNAL OF ENDOCRINOLOGY

Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression

(2013) Rex A. Parker et al.   JOURNAL OF LIPID RESEARCH

Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice

(2013) Thomas Gautier et al.   JOURNAL OF LIPID RESEARCH

Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor inLdlr−/−mice versus hamsters

(2013) Christophe Gardès et al.   JOURNAL OF LIPID RESEARCH

Mice with Chimeric Livers Are an Improved Model for Human Lipoprotein Metabolism

(2013) Ewa C. S. Ellis et al.   PLoS One

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

(2012) Luciano Adorini et al.   DRUG DISCOVERY TODAY

Farnesoid X Receptor Induces Murine Scavenger Receptor Class B Type I via Intron Binding

(2012) Guodong Li et al.   PLoS One

Cytochrome P450s in the synthesis of cholesterol and bile acids - from mouse models to human diseases

(2011) Gregor Lorbek et al.   FEBS Journal

Farnesoid X Receptor Activation Prevents the Development of Vascular Calcification in ApoE −/− Mice With Chronic Kidney Disease

(2010) Shinobu Miyazaki-Anzai et al.   CIRCULATION RESEARCH

Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist

(2010) G. Rizzo et al.   MOLECULAR PHARMACOLOGY

A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia

(2009) Mark J. Evans et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/−and apoE−/−mice

(2009) Helen B. Hartman et al.   JOURNAL OF LIPID RESEARCH

Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

(2009) Philippe Lefebvre et al.   PHYSIOLOGICAL REVIEWS

Antiatherosclerotic effect of farnesoid X receptor

(2008) Andrea Mencarelli et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes

(2008) Cédric Langhi et al.   FEBS LETTERS

High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis

(2008) Frank G. Schaap et al.   HEPATOLOGY